This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PerkinElmer (PKI) Beats on Q1 Earnings, Hikes '19 Guidance
by Zacks Equity Research
PerkinElmer's (PKI) Q1 earnings gain from top-line growth, solid show by Diagnostics segment and strong margins. However, negative currency movement remains a headwind.
Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.
Cerner (CERN) Earnings and Revenues Meet Estimates in Q1
by Zacks Equity Research
Cerner (CERN) gains from Professional Services unit in first-quarter 2019. A decline in bookings raises concern.
Zacks.com featured highlights include: PepsiCo, Raymond James, Kansas City Southern, Fortive and Abbott Laboratories
by Zacks Equity Research
Zacks.com featured highlights include: PepsiCo, Raymond James, Kansas City Southern, Fortive and Abbott Laboratories
Varian (VAR) Q2 Earnings Lag Estimates, Gross Orders Surge
by Zacks Equity Research
Varian (VAR) gains from solid segmental contributions in Q2, raises revenue guidance.
Align Technology (ALGN) Beats on Q1 Earnings, Margins Down
by Zacks Equity Research
Align Technology (ALGN) reports promising top-line numbers on double-digit increase in Invisalign case shipments from a year ago.
Solid Sales Growth Makes These 5 Stocks Worth Buying Now
by Swayta Shah
Sales growth is an early indicator of the company's future earnings performance.
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid
by Zacks Equity Research
Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.
Abbott (ABT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.28% and 0.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
5 Spectacular Large Cap Earnings Charts
by Tracey Ryniec
Which large cap earnings reports should you be watching this week?
Can Medical Devices Strength Drive Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.
Will Abbott's (ABT) Steady Overall Growth Aid Q1 Earnings?
by Zacks Equity Research
At the end of 2018, Abbott (ABT) posts some encouraging data, buoying investors' optimism on its Diabetes Care segment.
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $78.67 in the latest trading session, marking a +0.19% move from the prior day.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $79.50, marking a -0.15% move from the previous day.
Nevro (NVRO) Plagued by Issues in Australia & Stiff Rivalry
by Zacks Equity Research
Nevro's (NVRO) international sales get affected by weakness in Australia.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $78.23 in the latest trading session, marking a +0.33% move from the prior day.
Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip
by Zacks Equity Research
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.
Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm
by Zacks Equity Research
Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.
Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue
by Zacks Equity Research
Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.
6 Excellent Dividend Growth Stocks to Buy Now
by Sweta Killa
The return of volatility with the escalation of global growth concerns and the risk of recession in the United States raises the appeal for dividend growth stocks.
Varian (VAR) Scales New 52-Week High on Solid Prospects
by Zacks Equity Research
The key growth driving factor for Varian (VAR) in the past year has been increasing net sales from major business segments.
Baxter (BAX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Abbott's (ABT) HeartMate 3 Pump Study Shows Favorable Results
by Zacks Equity Research
The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.